Beijing, China / Orlando, USA – Recently, the American Diabetes Association's 84th Scientific Sessions opened grandly at the Orange County Convention Center in Orlando, Florida, bringing together top experts in diabetes research and treatment from around the world. Gan & Lee Pharmaceuticals (referred to as Gan & Lee, stock code: 603087.SH), as a leader in the field of diabetes treatment in China and the only Chinese pharmaceutical company participating in the exhibition, attracted many industry professionals for exchanges and discussions.

At the medical information booth area, the Gan & Lee team showcased the latest research progress of three innovative drugs: GZR18, GZR4, and GZR101, as well as the company's overseas pipeline products. They focused on presenting the preclinical and clinical data of innovative drugs disclosed at this ADA conference, while also displaying the clinical data of publicly available insulin biosimilars organized in support of the US FDA application, laying a solid and effective foundation for the upcoming clinical trials and product launches in the US market.

On the first day of the conference, Professor Ji Linong from Peking University People's Hospital, along with Dr. Xing Wancai and Dr. Chen Wei from Gan & Lee Pharmaceuticals, jointly conducted an oral poster presentation, sharing the latest breakthrough data of the company's three innovative products: GZR18 achieved an 18.6% weight reduction in the obese population in China; both GZR4 and GZR101 showed excellent pharmacokinetic and pharmacodynamic characteristics in preclinical studies. This presentation received widespread attention from the academic community, fully demonstrating Gan & Lee's leading position and scientific research strength in the field of diabetes frontier research.

Gan & Lee Pharmaceuticals has always adhered to the path of innovation, dedicated to solving challenging health problems in society. Dr. Li Zhi, Chief Business Officer (CBO), stated in an interview: “As a representative enterprise in the endocrine field, we are very honored to share our latest research achievements and progress at the American Diabetes Association's 84th Scientific Sessions. Gan & Lee has always pursued global innovation, adhering to the original intention of developing medicines driven by patients' needs. For example, through a long-term understanding of the medication needs of patients and doctors, we found that a significant proportion of diabetes patients receiving GLP-1 treatment discontinue the medication due to initial side effects, resulting in poor treatment outcomes. Gan & Lee's GZR18 is based on patient needs, with the molecule having unique pharmacokinetic characteristics, a longer half-life, and an extended time to peak, which helps patients better overcome side effects and build tolerance. At the same time, GZR18 has the potential for bi-weekly dosing, which we believe can greatly improve patient medication adherence and enhance long-term treatment outcomes.”

In the future, Gan & Lee Pharmaceuticals will continue to increase R&D investment, deepen international cooperation and exchanges, and explore more overseas markets, contributing to improving the treatment status of diabetes patients worldwide.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.